Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

La Chaux-de-Fonds, Switzerland and Shanghai, China. October 12, 2020, Oct. 12, 2020 (GLOBE NEWSWIRE) — Rhizen Pharmaceuticals S. A. (Rhizen), a Switzerland-based privately held clinical-stage biopharmaceutical company, and Curon Biopharmaceutical Limited (Curon), a clinical-stage innovative biopharmaceutical company with facility in Shanghai announced today that they have entered into an exclusive licensing agreement for the development […]

Myanmar: Humanitarian Fund Update (As of 30 September 2020)

The Myanmar Humanitarian Fund (MHF) mobilizes resources for humanitarian actors to respond to critical humanitarian needs in Myanmar. It provides funding to both national and international humanitarian organizations for activities that are in line with…

Myanmar Reports 1,910 New COVID-19 Cases, 48 New Deaths

The total number of COVID-19 cases in Myanmar increased to 27,974 as of yesterday, according to a release from the Ministry of Health and Sports.A total of 1,910 more COVID-19 confirmed cases were reported in the country.The death toll reached 646 with…

Posted in Health October 12, 2020

Icebreaker Returns From A-Year-Long Expedition to North Pole

An icebreaker belonging to Germany’s Alfred Wegener Institute (AWI) returned to Germany Monday with what the scientists on board say is proof of a dying Arctic Ocean and warnings of ice-free summers, after a more than yearlong expedition that included …

Posted in General October 12, 2020